Inaugural Global Business Summit in Jakarta convened to advance sustainable BRI Infrastructure Cooperation for SDGs
JAKARTA, Indonesia, May 31, 2025 /PRNewswire/ -- The "Inaugural Global Business Summit on Belt and Road Infrastructure Investment for Better Business Better World and Sustainable Development Goals" (the Summit) officially opened on May 25 in Jakarta. The Summit is co-hosted by the Government of Indonesia, the United Nations Global Compact "Sustainable Infrastructure for the Belt and Road Initiative to Accelerate the SDGs" Action Platform (UN Global Compact BRI for SDG Action Platform), THK Forum, United in Diversity Foundation (UID), the Indonesian Chamber of Commerce and Industry (KADIN), UN Global Compact Network Indonesia (IGCN), International Chamber of Commerce (ICC), and the Sustainable Development Solutions Network (SDSN).
In keynote addresses, UN Under-Secretary-General Li Junhua emphasized the imperative for "low-carbon, resilient, and universally accessible infrastructure" while the UN Assistant Secretary General, and Executive Director of UN Global Compact Sanda Ojiambo outlined four strategic priorities for businesses: adopting science-based decarbonization targets, prioritizing circular economy principles, engaging local communities, and leveraging blended finance. Xiamen Airlines Chairman Zhao Dong highlighted the pivotal role of aviation connectivity in advancing the "Air Silk Road".
The summit yielded substantive outcomes, including the launch of the report Transition Finance for Sustainable Development of Traditional Industries and nine cross-sector initiatives spanning green energy transition, SME empowerment, and global health cooperation. A landmark Joint Statement by the UNGC BRI for SDG Action Platform High-Level Steering Committee reaffirmed BRI's role as a global public good for infrastructure investments and business participation, committing to sustainable development through responsible business and multi-stakeholder partnerships across sectors including healthcare, energy, telecommunications, construction, manufacture, transportation, food, agriculture and digital infrastructure.
Four expert roundtables addressed critical themes: sustainable supply chains in green minerals, healthcare innovation, ESG compliance, and green industrial park development. Marking the 75th anniversary of China-Indonesia diplomatic ties, UN resident coordinator's office in Indonesia and China joined hands with UN Global Compact company participants to co-launch Sino-Indonesia Corporate Communities Action Network for sustainable development to enhance sustainable communities and SDGs. Business leaders endorsed establishing an annual business summit mechanism to ensure BRI projects align with SDGs and promote international standard and private sector best practices.
The summit concluded with a unified call to action, underscoring shared responsibility in building an inclusive, climate-resilient future through strengthened BRI collaboration. This inaugural event has established a new paradigm for public-private partnerships in sustainable infrastructure development, setting the stage for long-term, principled cooperation.
View original content:https://www.prnewswire.com/apac/news-releases/inaugural-global-business-summit-in-jakarta-convened-to-advance-sustainable-bri-infrastructure-cooperation-for-sdgs-302469699.html
SOURCE UN Global Compact
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target CHICAGO, June 1, 2025 /PRNewswire/ -- Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system against prostate cancer cells, showing promise in patients with advanced disease who have progressed after multiple lines of therapy. These first data on pasritamig, from the first-in-human study, demonstrate that pasritamig appears well-tolerated and exhibits a promising antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting the potential of KLK2 as a novel target for T-cell engagement in advanced disease.1 These data were presented as an oral presentation (Abstract #5017) at the 2025 American Society of Clinical Oncology Annual Meeting and published simultaneously in The Journal of Clinical Oncology. Pasritamig is a novel T-cell engager designed to bind both CD3 on T-cells and KLK2—a prostate-specific antigen with minimal expression outside of the prostate. Pasritamig activates T-cells by binding to CD3 and directing them to KLK2- expressing tumor cells, engaging the body's immune system to specifically target these cancerous cells. This differentiated approach aims to deliver a targeted treatment for patients with advanced prostate cancer, while potentially reducing the high-grade toxicities historically associated with T-cell engagers. "These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer," said Capucine Baldini*, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author. "The data show a promising safety profile, with manageable adverse events and no AEs leading to treatment discontinuations or ICANS observed, with 40 percent of patients having no treatment-related AEs at all. Given the limited treatment options for mCRPC, these findings support further investigation of pasritamig and the role of KLK2-targeted T-cell therapies as a potential new approach for patients with aggressive disease." "Metastatic castration-resistant prostate cancer remains one of the most difficult stages of prostate cancer to treat, particularly for patients who haven't responded well to previous treatments," said Jeff Infante, M.D., Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. "This investigational approach underscores our commitment to developing innovative and practice-changing medicines that are well-tolerated and can be easily administered in community practice settings." The Phase 1 first-in-human study (NCT04898634) evaluated 174 patients with ages ranging from 36 to 89 years old and on average having received four prior therapies (range 1-13). The recommended phase 2 dose (RP2D) of pasritamig was 3.5mg on day 1, 18mg on day 8, 300mg intravenously on day 15 and then once every six weeks. The RP2D safety group also included patients treated once every three weeks as the toxicity profiles were very similar. The RP2D efficacy group only included patients treated at the RP2D once every six weeks.1 Within the RP2D safety group (n=45), treated once every three or six weeks, 100 percent had previously received androgen receptor pathway inhibitors, 75.6 percent had undergone taxane chemotherapy, and 37.8 percent had been treated with Lutetium 177 vipivotide tetraxetan prostate-specific membrane antigen radioligand therapy.1 The most common treatment- related adverse events (TRAEs) were Grade 1/2 infusion-related reactions (24.4 percent), Grade 1 cytokine release syndrome (CRS) presenting as fever only (8.9 percent, no steroid or tocilizumab was administered) and no reports of higher grade CRS. No TRAEs leading to treatment discontinuation or dose reduction were reported and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Grade 3 TRAEs were infrequent with 4.4 percent of patients reporting transient AST/ALT increases and neutropenia. There were no dose-limiting toxicities reported. The favorable safety profile of the RP2D regimen enabled convenient outpatient administration on a patient-friendly, once-every-six-weeks schedule.1 Of the patients in the RP2D efficacy group (n=33), treated once every six weeks, 42.4 percent achieved a 50 percent or greater reduction in their prostate-specific antigen (PSA) levels with a median rPFS of 7.9 months (95 percent confidence interval [CI] 2.9, not estimable [NE]) and 21.2 percent of patients continuing therapy. Treatment with pasritamig showed durable disease control and rPFS that compares favorably to historical data in heavily pretreated patients with mCRPC.1 Metastatic castration-resistant prostate cancer occurs in a significant portion of prostate cancer patients, with many progressing despite initial therapies.2 Overall survival from diagnosis of mCRPC patients ranges from 13.5 to 31.6 months, and lower in patients who have progressed on therapy.3 Treatment options remain limited, underscoring the urgent need for safer and more effective therapies.4 About Pasritamig (JNJ-78278343)Pasritamig (JNJ-78278343) is an investigational T-cell-engaging bispecific antibody (bsAb) targeting human kallikrein 2 (KLK2) on prostate cancer cells and CD3 on T-cells. This approach is being evaluated in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), a patient population with limited treatment options. About Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic castration-resistant prostate cancer (mCRPC) is a challenging and aggressive stage of prostate cancer where the disease progresses despite androgen deprivation therapy.2 Patients often experience metastasis to bones and lymph nodes, leading to poor outcomes and limited treatment options, including chemotherapy and second-line hormone therapies.5 The median overall survival ranges from 13.5 to 31.6 months depending on the site of metastasis, with a typical range of 15–36 months across the broader population.3,6 Survival rates can vary significantly depending on factors such as prior treatment history, disease burden, and response to therapy. The need for more effective treatments is critical, as the disease continues to impact a large number of men globally, with mCRPC being responsible for a substantial number of prostate cancer-related deaths. About Johnson & JohnsonAt Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at or at Follow us at @JNJInnovMed. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking StatementsThis press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of JNJ-78278343. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Source: Johnson & Johnson *Dr. Capucine Baldini has provided consulting, advisory, and speaking services to Johnson & Johnson; Dr. Baldini has not been paid for any media work. 1 Baldini, C., et al. Phase 1 Study Results of Pasritamig (JNJ-78278343) in Metastatic Castration-Resistant Prostate Cancer. 2025 American Society of Clinical Oncology Annual Meeting. June 2025.2 Scher, H. I., et al. (2016). "Treatment of castration-resistant prostate cancer: Current and future strategies." Nature Reviews Clinical Oncology, 13(10), 577-590.3 Wallace KL, Landsteiner A, Bunner SH, Engel-Nitz NM, Luckenbaugh AN. Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. Cancer Causes Control. 2021;32(12):1365-1374. doi:10.1007/s10552-021-01484-44 Ravi P, Mateo J, Lorente D, et al. Clinical prognostic factors and management of metastatic castration-resistant prostate cancer: a population-based study. PLoS One. 2015;10(10):e0139440. doi:10.1371/ Ryan, C. J., et al. (2015). "Abiraterone acetate in metastatic prostate cancer: A new era." Journal of Clinical Oncology, 33(10), 1051-1060.6 Kawahara, T., Saigusa, Y., Yoneyama, S. et al. Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. BMC Cancer 23, 214 (2023). Media contacts:Oncology Media Relations oncology_media_relations@ Investor contact:Lauren Johnsoninvestor-relations@ U.S. Medical Inquiries +1 800 526-7736 View original content to download multimedia: SOURCE Johnson & Johnson Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Pan-Africanists Unite: Preparations Begin for 80th Anniversary of Historic Manchester Congress
ACCRA, Ghana, May 29, 2025 /PRNewswire/ -- The Pan-African Progressive Front (PPF), in collaboration with the Ghana Socialist Movement and Pan Africanism Today, convened a landmark online conference to initiate discussions and preparations for the upcoming 80th anniversary of the pivotal Fifth Pan-African Congress held in Manchester in 1945. Bringing together more than sixty influential pan-Africanists from 32 countries—including representatives from the USA and Brazil—the event underscored the enduring legacy and urgency of pan-African unity, decolonization, and the struggle against imperialism. The conference opened with Albie Walls of the All-African People's Revolutionary Party, who emphasized the far-reaching impact of the Manchester Congress on Africa's liberation movements and called for renewed clarity and action toward unifying progressive forces across the continent. Roland Diagne (FERNET, Senegal) highlighted the ongoing relevance of anti-neocolonial resolutions adopted at the Manchester Congress, noting the resurgence of patriotism and demands for true sovereignty, especially in the Sahel region. Diagne voiced concerns about external military interventions and stressed the need for ECOWAS to return to its foundational mission. Kwesi Pratt Jr., a journalist and member of the PPF organizing committee, presented a strategic roadmap for the anniversary celebration. He proposed the establishment of a central committee and specialized commissions on trade union issues, women's rights, and youth engagement, as well as mechanisms for mass mobilization and political power analysis. The meeting also featured voices from key organizations: Imani Na Umoja (African Party for the Independence of Guinea and Cape Verde) advocated for a comprehensive congress to unite organizations pursuing shared goals. Ouzayrou Mamane (Pan-African Movement for Reparations, Justice and Restoration of Historical Memory) insisted that reparations for former colonies are vital for economic independence and historical justice. Amina Hamani (MORFEPAN, Niger) urged transforming pan-Africanism from a symbol into an actionable tool for achieving full independence, amid renewed foreign interference. Saddam Alktif (CODESA) emphasized the unresolved crisis in Western Sahara, stating that pan-Africanism's objectives remain incomplete while occupation persists. Humphrey Quaye (PPF) reiterated the organization's commitment to fighting imperialism and neocolonialism, and called for collective action. Eighteen delegates contributed to a lively debate, culminating in Albie Walls' closing remarks and the formation of a central organizing committee. The PPF announced plans for further meetings and intensified coordination to ensure the 80th anniversary serves as a catalyst for real, unified progress in Africa's ongoing liberation and development. View original content: SOURCE Pan-African Progressive Front Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
4 hours ago
- Yahoo
Bangladesh ex-PM Hasina charged with ‘systematic attack' as trial opens
Fugitive former Prime Minister Sheikh Hasina orchestrated a 'systematic attack' on protests against her government, Bangladeshi prosecutors have said at the opening of her trial over last year's deadly crackdown. 'Upon scrutinising the evidence, we reached the conclusion that it was a coordinated, widespread and systematic attack,' Mohammad Tajul Islam, chief prosecutor at Bangladesh's domestic International Crimes Tribunal (ICT), told the court in his opening speech on Sunday. 'The accused unleashed all law enforcement agencies and her armed party members to crush the uprising,' Islam said as he charged the 77-year-old former leader and two other officials of 'abetment, incitement, complicity, facilitation, conspiracy, and failure to prevent mass murder' during the student-led mass uprising. The United Nations says nearly 1,400 Bangladeshis were killed between July and August 2024 when Hasina's government launched a brutal campaign to silence the protesters. Bangladesh has charged her with crimes against humanity over the killings. Hasina – who remains in self-imposed exile in neighbouring India, her old ally – has rejected the charges as politically motivated. She fled by helicopter to New Delhi in August last year after the nationwide protests ended her 'autocratic' 15-year rule marked by allegations of repeated human rights violations, including attacks, imprisonment, and even targeted killings of opposition figures, dissenters, and critics. She has since defied an arrest warrant and extradition order to return to ICT is also prosecuting former senior figures connected to the ousted government of Hasina and her now-banned Awami League party, including former Interior Minister Asaduzzaman Khan Kamal and former police chief Chowdhury Abdullah Al-Mamun. Their prosecution has been a key demand of several political parties now jostling for power. The interim government has promised to hold elections before June 2026. Prosecutors submitted their report in the case against Hasina last month, with the court expected to issue formal charges on Sunday. ICT chief prosecutor Tajul Islam said on May 12 that Hasina faces at least five charges, including 'abetment, incitement, complicity, facilitation, conspiracy and failure to prevent mass murder during the July uprising'. Investigators have collected video footage, audio clips, Hasina's phone conversations, records of helicopter and drone movements, as well as statements from victims of the crackdown as part of their probe. The ICT opened its first trial connected to the previous government on May 25. In that case, eight police officials face charges of crimes against humanity over the killing of six protesters on August 5, 2024 – the day Hasina fled the country. Four of the officers are in custody and four are being tried in absentia. The ICT was set up by Hasina in 2009 to investigate crimes committed by the Pakistani army during Bangladesh's war for independence in 1971. It sentenced numerous prominent political opponents to death, and many saw it as a means for Hasina to eliminate rivals.
